METHODS FOR DETECTING ANTIBODIES TO HAV 3C PROTEINASE
US Application 60/013,333
Filed on 1996-03-13
Filed on 1996-03-13
CELLS EXPRESSING BOTH HUMAN CD4 AND A HUMAN FUSION ACCESSORY FACTOR ASSOCIATED WITH HIV INFECTION
US Application 60/010,854
Filed on 1996-01-30
Filed on 1996-01-30
NEUTRALIZING MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS
US Application 60/003,931
Filed on 1995-09-18
Filed on 1995-09-18
PRODUCTION OF INFECTIOUS RESPIRATORY SYNCYTIAL VIRUS FROM CLONED NUCLEOTIDE SEQUENCES
US Application 60/007,083
Filed on 1995-09-27
Filed on 1995-09-27
SOLUBLE FACTOR PRODUCED BY CD8-POSITIVE T CELLS FROM HIV-INFECTED INDIVIDUALS THAT INHIBITS ACUTE INFECTION AND VIRAL REPLICATION IN...
US Application 60/005,566
Filed on 1995-10-18
Filed on 1995-10-18
ENHANCEMENT OF STEM CELL ENGRAFTMENT AT LOW IRRADIATION DOSES BY PRETREATING THE RECIPIENT WITH GRANULOCYTE COLONY STIMULATING...
US Application 60/001,386
Filed on 1995-07-21
Filed on 1995-07-21
HEPATITIS A VIRUS CLONES ADAPTED FOR GROWTH IN AFRICAN GREEN MONKEY KIDNEY (AGMK) CELLS AND VACCINES COMPRISING SAID CLONES
US Application 60/147,637
Filed on 1999-08-06
Filed on 1999-08-06
COVID-19 Technologies Licensed Globally Through WHO Program Win LES Deals of Distinction Award
NIAID TTIPO’s extraordinary efforts in “COVID-19 Technologies Licensed Globally Through WHO Program” was recognized by the Licensing Executives Society (U.S.A. & Canada) in 2022 with a Deals of Distinction Award in the Industry-University-Government Interface Sector. This award acknowledged the collaborative efforts put forth by the WHO, Medicines Patent Pool (MPP) and the NIH for COVID-19 technologies licensed globally through the WHO program.
NIAID Won Patents for Humanity: COVID-19 Category Award for Stabilized Coronavirus Spike Proteins
The United States Patent and Trademark Office (USPTO) recognized NIAID TTIPO’s public health-centered patent management efforts with the Patents for Humanity: COVID-19 category award with the USPTO announcing the award on December 15, 2022. NIAID, Scripps Research Institute, and Dartmouth College invented stabilized coronavirus spike proteins, which were essential to the development of the COVID-19 vaccines used today. The vaccines that incorporate these stabilized spike proteins have been instrumental in combating the COVID-19 pandemic.
NIAID Won 2022 FLC Impact Award for Industry Partnerships That Facilitated NIAID Trials to Support Authorization of COVID-19 Vaccine Candidates
In response to the COVID-19 outbreak, researchers and technology transfer professionals at NIAID accelerated collaborations with COVID-19 vaccine developers that enabled the rapid study, emergency authorization and public use of urgently needed vaccines.